Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 882

1.

Acute infection and subsequent subclinical reactivation of herpes simplex virus-2 after vaginal inoculation of rhesus macaques.

Lo M, Zhu J, Hansen SG, Carroll T, Farr Zuend C, Nöel-Romas L, Ma ZM, Fritts L, Huang ML, Sun S, Huang Y, Koelle D, Picker LJ, Burgener A, Corey L, Miller CJ.

J Virol. 2018 Oct 17. pii: JVI.01574-18. doi: 10.1128/JVI.01574-18. [Epub ahead of print]

2.

Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons.

Ford ES, Magaret AS, Spak CW, Selke S, Kuntz S, Corey L, Wald A.

AIDS. 2018 Nov 13;32(17):2525-2531. doi: 10.1097/QAD.0000000000002002.

PMID:
30289810
3.

Environmental exposure to perchlorate: A review of toxicology and human health.

Pleus RC, Corey LM.

Toxicol Appl Pharmacol. 2018 Nov 1;358:102-109. doi: 10.1016/j.taap.2018.09.001. Epub 2018 Sep 2. Review.

PMID:
30184474
4.

A Fixed Spatial Structure of CD8+ T Cells in Tissue during Chronic HSV-2 Infection.

Schiffer JT, Swan DA, Roychoudhury P, Lund JM, Prlic M, Zhu J, Wald A, Corey L.

J Immunol. 2018 Sep 1;201(5):1522-1535. doi: 10.4049/jimmunol.1800471. Epub 2018 Jul 25.

PMID:
30045971
5.

Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals.

Agyemang E, Magaret AS, Selke S, Johnston C, Corey L, Wald A.

J Infect Dis. 2018 Oct 20;218(11):1691-1699. doi: 10.1093/infdis/jiy372.

PMID:
30020484
6.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.

Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.

7.

Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants.

Boucoiran I, Mayer BT, Krantz EM, Marchant A, Pati S, Boppana S, Wald A, Corey L, Casper C, Schiffer JT, Gantt S.

Pediatr Infect Dis J. 2018 Jul;37(7):627-631. doi: 10.1097/INF.0000000000001877.

PMID:
29889809
8.

Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa.

Janes H, Corey L, Ramjee G, Carpp LN, Lombard C, Cohen MS, Gilbert PB, Gray GE.

AIDS Res Hum Retroviruses. 2018 Aug;34(8):645-656. doi: 10.1089/AID.2018.0031. Epub 2018 Jun 19.

PMID:
29732896
9.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L.

Stat Commun Infect Dis. 2017 Jan;9(1). pii: 20160001. doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6.

10.

Determination of Thresholds of Radioactive Iodine Uptake Response With Clinical Exposure to Perchlorate: A Pooled Analysis.

Bruce GM, Corey LM, Pearce EN, Braverman LE, Pleus RC.

J Occup Environ Med. 2018 Apr;60(4):e199-e206. doi: 10.1097/JOM.0000000000001239.

PMID:
29200191
11.

Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition.

Ramchandani M, Selke S, Magaret A, Barnum G, Huang MW, Corey L, Wald A.

Sex Transm Infect. 2017 Nov 25. pii: sextrans-2017-053244. doi: 10.1136/sextrans-2017-053244. [Epub ahead of print]

PMID:
29175899
12.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

13.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Van Tieu H, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network.

PLoS Med. 2017 Nov 14;14(11):e1002435. doi: 10.1371/journal.pmed.1002435. eCollection 2017 Nov.

14.

Adoptive Immunotherapy of Viral Infections: Should Infectious Disease Embrace Cellular Immunotherapy?

Boeckh M, Corey L.

J Infect Dis. 2017 Nov 15;216(8):926-928. doi: 10.1093/infdis/jix360. No abstract available.

PMID:
29029104
15.

Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children.

Matrajt L, Gantt S, Mayer BT, Krantz EM, Orem J, Wald A, Corey L, Schiffer JT, Casper C.

Sci Rep. 2017 Oct 12;7(1):13105. doi: 10.1038/s41598-017-12994-0.

16.

Broadly neutralizing antibodies to prevent HIV-1.

Cohen MS, Corey L.

Science. 2017 Oct 6;358(6359):46-47. doi: 10.1126/science.aap8131. No abstract available.

PMID:
28983040
17.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov.

18.

Valganciclovir for the Suppression of Epstein-Barr Virus Replication.

Yager JE, Magaret AS, Kuntz SR, Selke S, Huang ML, Corey L, Casper C, Wald A.

J Infect Dis. 2017 Jul 15;216(2):198-202. doi: 10.1093/infdis/jix263.

19.

Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation.

Peng T, Chanthaphavong RS, Sun S, Trigilio JA, Phasouk K, Jin L, Layton ED, Li AZ, Correnti CE, De van der Schueren W, Vazquez J, O'Day DR, Glass IA, Knipe DM, Wald A, Corey L, Zhu J.

J Exp Med. 2017 Aug 7;214(8):2315-2329. doi: 10.1084/jem.20160581. Epub 2017 Jun 29.

20.

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.

Gilbert PB, Excler JL, Tomaras GD, Carpp LN, Haynes BF, Liao HX, Montefiori DC, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kijak GH, Tovanabutra S, Francis DP, Lee C, Sinangil F, Berman PW, Premsri N, Kunasol P, O'Connell RJ, Michael NL, Robb ML, Morrow R, Corey L, Kim JH.

PLoS One. 2017 May 11;12(5):e0176428. doi: 10.1371/journal.pone.0176428. eCollection 2017.

21.

Transient Oral Human Cytomegalovirus Infections Indicate Inefficient Viral Spread from Very Few Initially Infected Cells.

Mayer BT, Krantz EM, Swan D, Ferrenberg J, Simmons K, Selke S, Huang ML, Casper C, Corey L, Wald A, Schiffer JT, Gantt S.

J Virol. 2017 May 26;91(12). pii: e00380-17. doi: 10.1128/JVI.00380-17. Print 2017 Jun 15.

22.

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults.

Huang Y, Zhang L, Ledgerwood J, Grunenberg N, Bailer R, Isaacs A, Seaton K, Mayer KH, Capparelli E, Corey L, Gilbert PB.

MAbs. 2017 Jul;9(5):792-800. doi: 10.1080/19420862.2017.1311435. Epub 2017 Apr 3.

23.

Exposure of the US Population to Nitrate, Thiocyanate, Perchlorate, and Iodine Based on NHANES 2005-2014.

Corey LM, Bell GP, Pleus RC.

Bull Environ Contam Toxicol. 2017 Jul;99(1):83-88. doi: 10.1007/s00128-017-2077-7. Epub 2017 Apr 1.

PMID:
28365805
24.

Preventing acquisition of HIV is the only path to an AIDS-free generation.

Corey L, Gray GE.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3798-3800. doi: 10.1073/pnas.1703236114. Epub 2017 Mar 30. No abstract available.

25.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.

J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086.

26.

Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem Cell Transplant Recipients With CMV Pneumonia.

Boeckh M, Stevens-Ayers T, Travi G, Huang ML, Cheng GS, Xie H, Leisenring W, Erard V, Seo S, Kimball L, Corey L, Pergam SA, Jerome KR.

J Infect Dis. 2017 May 15;215(10):1514-1522. doi: 10.1093/infdis/jix048.

27.

β-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice.

Varga ZV, Matyas C, Erdelyi K, Cinar R, Nieri D, Chicca A, Nemeth BT, Paloczi J, Lajtos T, Corey L, Hasko G, Gao B, Kunos G, Gertsch J, Pacher P.

Br J Pharmacol. 2018 Jan;175(2):320-334. doi: 10.1111/bph.13722. Epub 2017 Feb 22.

28.

Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract.

Posavad CM, Zhao L, Dong L, Jin L, Stevens CE, Magaret AS, Johnston C, Wald A, Zhu J, Corey L, Koelle DM.

Mucosal Immunol. 2017 Sep;10(5):1259-1269. doi: 10.1038/mi.2016.118. Epub 2017 Jan 4.

29.

Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.

Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Fife K, Selke S, Huang ML, Stobernack HP, Zimmermann H, Corey L, Birkmann A, Ruebsamen-Schaeff H.

JAMA. 2016 Dec 20;316(23):2495-2503. doi: 10.1001/jama.2016.18189. Erratum in: JAMA. 2017 Feb 14;317(6):648.

PMID:
27997653
30.

Herpes Simplex Virus Type 1 Shedding in Tears and Nasal and Oral Mucosa of Healthy Adults.

Ramchandani M, Kong M, Tronstein E, Selke S, Mikhaylova A, Magaret A, Huang ML, Johnston C, Corey L, Wald A.

Sex Transm Dis. 2016 Dec;43(12):756-760.

31.

A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.

Hertz T, Logan MG, Rolland M, Magaret CA, Rademeyer C, Fiore-Gartland A, Edlefsen PT, DeCamp A, Ahmed H, Ngandu N, Larsen BB, Frahm N, Marais J, Thebus R, Geraghty D, Hural J, Corey L, Kublin J, Gray G, McElrath MJ, Mullins JI, Gilbert PB, Williamson C.

Vaccine. 2016 Nov 11;34(47):5792-5801. doi: 10.1016/j.vaccine.2016.09.054. Epub 2016 Oct 15.

32.

Dynamics of Persistent Oral Cytomegalovirus Shedding During Primary Infection in Ugandan Infants.

Mayer BT, Matrajt L, Casper C, Krantz EM, Corey L, Wald A, Gantt S, Schiffer JT.

J Infect Dis. 2016 Dec 1;214(11):1735-1743. Epub 2016 Sep 20.

33.

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.

Churchyard G, Mlisana K, Karuna S, Williamson AL, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N, Yu C, Mkhize NN, Hermanus T, Allen M, Pensiero M, Barnett SW, Gray G, Bekker LG, Montefiori DC, Kublin J, Corey L.

PLoS One. 2016 Sep 1;11(9):e0161753. doi: 10.1371/journal.pone.0161753. eCollection 2016.

34.

Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa.

Schiffer JT, Swan DA, Magaret A, Schacker TW, Wald A, Corey L.

PLoS One. 2016 Jun 10;11(6):e0155124. doi: 10.1371/journal.pone.0155124. eCollection 2016.

35.

In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 Reactivation.

Milman N, Zhu J, Johnston C, Cheng A, Magaret A, Koelle DM, Huang ML, Jin L, Klock A, Layton ED, Corey L.

J Infect Dis. 2016 Jul 1;214(1):23-31. doi: 10.1093/infdis/jiw091. Epub 2016 Apr 25.

36.

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.

Gray GE, Mayer KH, Elizaga ML, Bekker LG, Allen M, Morris L, Montefiori D, De Rosa SC, Sato A, Gu N, Tomaras GD, Tucker T, Barnett SW, Mkhize NN, Shen X, Downing K, Williamson C, Pensiero M, Corey L, Williamson AL.

Clin Vaccine Immunol. 2016 Jun 6;23(6):496-506. doi: 10.1128/CVI.00717-15. Print 2016 Jun.

37.

No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy.

Edlefsen PT, Birkmann A, Huang ML, Magaret CA, Kee JJ, Diem K, Goldner T, Timmler B, Stoelben S, Ruebsamen-Schaeff H, Zimmermann H, Warren T, Wald A, Corey L.

J Infect Dis. 2016 Jul 15;214(2):258-64. doi: 10.1093/infdis/jiw129. Epub 2016 Apr 7.

38.

In Situ Staining and Laser Capture Microdissection of Lymph Node Residing SIV Gag-Specific CD8+ T cells--A Tool to Interrogate a Functional Immune Response Ex Vivo.

Tjernlund A, Burgener A, Lindvall JM, Peng T, Zhu J, Öhrmalm L, Picker LJ, Broliden K, McElrath MJ, Corey L.

PLoS One. 2016 Mar 17;11(3):e0149907. doi: 10.1371/journal.pone.0149907. eCollection 2016.

39.

Approaches to preventative and therapeutic HIV vaccines.

Gray GE, Laher F, Lazarus E, Ensoli B, Corey L.

Curr Opin Virol. 2016 Apr;17:104-109. doi: 10.1016/j.coviro.2016.02.010. Epub 2016 Mar 15. Review.

40.

Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?

Gray GE, Laher F, Doherty T, Abdool Karim S, Hammer S, Mascola J, Beyrer C, Corey L.

PLoS Biol. 2016 Mar 2;14(3):e1002372. doi: 10.1371/journal.pbio.1002372. eCollection 2016 Mar. Review. Erratum in: PLoS Biol. 2016 Jun;14(6):e1002487.

41.

Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants.

Gantt S, Orem J, Krantz EM, Morrow RA, Selke S, Huang ML, Schiffer JT, Jerome KR, Nakaganda A, Wald A, Casper C, Corey L.

J Infect Dis. 2016 Jul 1;214(1):36-44. doi: 10.1093/infdis/jiw076. Epub 2016 Feb 24.

42.

Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons.

Bender Ignacio RA, Goldman JD, Magaret AS, Selke S, Huang ML, Gantt S, Johnston C, Phipps WT, Schiffer JT, Zuckerman RA, McClelland RS, Celum C, Corey L, Wald A, Casper C.

Infect Agent Cancer. 2016 Feb 10;11:7. doi: 10.1186/s13027-016-0052-2. eCollection 2016.

43.

Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.

Dimitrov D, Kublin JG, Ramsey S, Corey L.

EBioMedicine. 2015 Nov 5;2(12):2062-9. doi: 10.1016/j.ebiom.2015.11.009. eCollection 2015 Dec.

44.

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes.

Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H, Stoelben S, Timmler B, Zimmermann H, Melhem MR, Van Wart SA, Rubino CM, Birkmann A.

Sci Transl Med. 2016 Feb 3;8(324):324ra15. doi: 10.1126/scitranslmed.aad6654.

45.

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.

Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, Kanesa-Thasan N, Bourguignon P, Collard A, Buchbinder S, Tomaras GD, McElrath J, Gray G, Kublin JG, Corey L, Gilbert PB.

Curr Opin Virol. 2016 Apr;17:57-65. doi: 10.1016/j.coviro.2016.01.007. Epub 2016 Jan 29. Review.

46.

Epilepsy After Febrile Seizures: Twins Suggest Genetic Influence.

Seinfeld SA, Pellock JM, Kjeldsen MJ, Nakken KO, Corey LA.

Pediatr Neurol. 2016 Feb;55:14-6. doi: 10.1016/j.pediatrneurol.2015.10.008. Epub 2015 Oct 31.

47.

Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding.

Johnston C, Corey L.

Clin Microbiol Rev. 2016 Jan;29(1):149-61. doi: 10.1128/CMR.00043-15. Review.

48.

Immune correlates of vaccine protection against HIV-1 acquisition.

Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS.

Sci Transl Med. 2015 Oct 21;7(310):310rv7. doi: 10.1126/scitranslmed.aac7732. Review.

49.

Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda.

Phipps W, Nakku-Joloba E, Krantz EM, Selke S, Huang ML, Kambugu F, Orem J, Casper C, Corey L, Wald A.

J Infect Dis. 2016 Feb 1;213(3):439-47. doi: 10.1093/infdis/jiv451. Epub 2015 Oct 20.

50.

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.

Moodie Z, Metch B, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, Bentley C, Gilbert PB, Robertson M, Kublin J, Corey L, Gray GE.

PLoS One. 2015 Sep 14;10(9):e0137666. doi: 10.1371/journal.pone.0137666. eCollection 2015.

Supplemental Content

Support Center